Fusion Antibodies
Fusion Antibodies are a Collaborative Research Organisation (CRO) with its headquarters based in Northern Ireland. We provide antibody discovery, engineering and supply, through to cell line development and have guided hundreds of projects through critical preclinical stages and our scientists, who are experts in early stage discovery of biologics, are dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry.
About us
Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CDRx™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Our world-class humanization and antibody optimization platforms harness the power of the natural somatic hypermutation space. To address remaining market needs in antibody discovery, Fusion is creating a breakthrough fully human antibody library (OptiMAL®) to capture the entire human antibody repertoire.
Currently in development, OptiMAL® is Fusion’s new mammalian antibody library – a discovery platform yielding fully human antibodies. OptiMAL® is for clients looking to streamline the discovery and preclinical optimization of novel antibodies. Incorporating Fusion Antibodies’ proprietary protein engineering technologies, the library eliminates the need for platform switching and reformatting common with other approaches. The output from OptiMAL® is a fully-human antibody with no need for further humanisation.
OptiMAL® is currently being used in four exciting proof of concept studies.
Highlights
- Antibody Discovery:
Hybridoma Generation
B Cell Screening
Antibody Sequencing - Antibody Engineering:
CDRx Humanization
Reformatting Toolkit
Antibody Development
Affinity Maturation - Antibody Supply:
Transient Protein Expression
cGMP Stable Cell Line Development
Antibody Characterization
Cell Line Development
Website | https://fusionantibodies.com/
Schedule a 1:1 business networking meeting with Fusion Antibodies
